America’s window of opportunity to beat back Covid-19 is closing
The United States has a chance to make things better before things get much, much worse. But much of the country appears to be squandering the opportunity.
The United States has a chance to make things better before things get much, much worse. But much of the country appears to be squandering the opportunity.
Measures of biological age have exploded into health research and have fueled hype around consumer tests. But the field of aging has still not settled…
CVS Health missed its Q1 projections and lowered its full-year outlook, citing medical cost hikes with Medicare Advantage patients. Its stock price slid.
The DEA is allowing annual and semi-annual production quotas for Schedule II drugs, after it became clear quarterly quotas would worsen shortages.
Three years ago, Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it’s backing out.
A heart attack or poor circulation from diabetes can wreak damage on blood vessels. Scientists want to use mitochondria to jump-start repairs.
In a rare observed case of self-treatment in a wild animal, scientists documented an orangutan applying a medicinal plant to a wound on his face.
An experimental gene therapy seems to alleviate skeletal defects tied to rare inherited disease, a new study shows.
A STAT Investigation: Brain biopsies on “vulnerable” patients at Mount Sinai set off alarm bells at FDA, documents show.
Walmart had grand ambitions, back in 2019, to grow a network of cheaper primary care clinics attached to its ubiquitous stores. Those ambitions are now…
Financial strain is created by inequitable health financing structures that overpay private academic medical centers at the expense of safety net hospitals.